VALUE trial

Introduction

Study characteristics:

• 15,245 hypertensive patients
• minimum age 50
• mean BP 155/87 mm Hg
• 31 countries
• at least one cardiovascular risk factor
• 92% previously treated with antihypertensives

Treatment:

• does titrated over period of 6 months
• valsartan (160 mg QD max) vs amlodipine (10 mg QD max)
• other agents added as needed
• mean follow-up of 4.2 years

Target BP

• < 140/90

Results:

• mean BP declined in both groups, but less with valsartan than with amlodipine*
• composite endpoint of adverse cardiovascular events did not differ between groups
• more myocardial infarctions in valsartan group*
• trend towards more stroke in valsartan group*
• less new onset diabetes in valsartan group

* mostly in 1st 6 months

More general terms

• clinical trial